In fact, a study by Mukherjee et al. suggested that mutant IDH may work synergistically with ATRX loss to drive alternative lengthening of telomere phenotype in gliomas, hence conferring a survival advantage in this subset of glioma patients [56]. The gene discussed is ATRX; the disease is central nervous system cancer.